IRVINE, Calif., March 14, 2024—Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced that Matt Thompson, President and CEO, will present at the Life Science Intelligence (LSI) USA ’24 Emerging Medtech Summit. Scheduled for March 20, 2024, at 10:55 am PT on Track 3 , Thompson will offer insights into the company’s innovative portfolio and its impact on vascular disease treatment.
Matt Thompson remarked, “At this pivotal juncture for Endologix, our involvement in the LSI US ’24 Emerging Medtech Summit underscores our dedication to spearheading innovation in vascular disease. It’s a privilege to highlight our pioneering solutions designed to enhance patient outcomes. The summit represents a unique platform for interaction with industry peers and thought leaders, enabling collaborations that are essential for shaping the future of healthcare.”
About Endologix
Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOURTM System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.
Media Contact:
Sandy Prietto
949-595-7240
sprietto@endologix.com
